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Summary
When hepatitis B virus (HBV)-specific CD8+ cytotoxic
T lymphocytes (CTLs) are adoptively transferred into
HBV transgenic mice, they enter the liver, recognize
antigen, secrete interferon  (IFN), inhibit viral repli-
cation, and kill their target cells, causing hepatitis. In
the current study, we examined the impact of antigen
recognition on the evolution of the activation pheno-
type, antiviral effector functions, expansion and con-
traction kinetics, and compartmentalization of the
transferred CTLs. The results reveal that noncytolytic
and cytolytic effector functions and expansion-con-
traction kinetics of the CTLs are regulated asynchro-
nously and in an oscillatory manner as a conse-
quence of antigen recognition in the liver and in
association with PD-1 upregulation. We suggest that
such oscillations maximize viral clearance and mini-
mize tissue injury during HBV infection and that poor
coordination of these events could lead to viral per-
sistence and chronic liver disease.
Introduction
Although it is widely accepted that a vigorous virus-
specific CD8+ T cell response is required to control
most viral infections, the extent to which the cytolytic
and noncytolytic functions of those T cells must be co-
ordinated for viral clearance to occur is not well de-
fined. Upon TCR engagement with peptide-MHC class
I complexes, CD8+ T cells massively expand (Flynn et
al., 1998; Murali-Krishna et al., 1998) and express multi-
ple effector functions, including cytotoxicity mediated
by perforin-granzyme and Fas-FasL pathways (Berke,
1995; Harty et al., 2000), and cytokine production such
as IFNγ and TNFα (Harty et al., 2000; Slifka et al., 1999).
These two effector functions differ in several ways.
First, cytotoxicity is limited to target cells that are in
direct contact with CD8+ T cells, whereas cytokine re-
lease can have both local and systemic consequences
(Slifka and Whitton, 2000). Second, cytotoxicity relies
on the presence of stored molecules in lytic granules or
FasL expression on their surface (Barry and Bleackley,
2002), whereas secretion of antiviral cytokines requires
de novo synthesis of effector molecules (Slifka et al.,
1999) upon encountering antigen. Third, most antigen-
specific CD8+ T cells constitutively express perforin
and granzyme B (grB), but not cytokines ex vivo, at the
peak of the antiviral immune response (Slifka et al.,
1999; Wherry et al., 2003b). Although these findings*Correspondence: fchisari@scripps.edusuggest that regulation of these two effector functions
is fundamentally different, the relative importance and
kinetics of CD8+ T cell-mediated IFNγ production and
cytolytic activity in controlling virus infection have re-
mained elusive. For example, although the rapid kine-
tics of CD8+ T cell cytokine induction by antigen has
been well characterized in vitro (Lalvani et al., 1997;
Slifka et al., 1999), the relationship between the kinetics
of CD8+ T cell expansion and contraction, cytokine and
activation marker expression, cytolytic effector func-
tion, viral clearance, and disease pathogenesis is not
completely understood.
We have previously studied the impact of antigen re-
cognition by adoptively transferred HBV-specific CD8+
CTLs on HBV replication and liver disease pathogene-
sis (Ando et al., 1993; Guidotti et al., 1996). In those
studies, we showed that antigen recognition in the liver
triggers the release of antiviral cytokines that inhibit vi-
ral replication noncytopathically (Guidotti et al., 1996)
and that it activates the cytolytic potential of these T
cells, resulting in a necroinflammatory liver disease
(Ando et al., 1993; Guidotti et al., 1996) with kinetics
that are delayed relative to the antiviral effect. In keep-
ing with these observations, we have recently shown
that the onset of viral clearance in HBV-infected chim-
panzees is tightly associated with the appearance of
IFNγ-producing virus-specific T cells as well as IFNγ
mRNA in the liver and that it is well underway long be-
fore the peak of liver disease (Guidotti et al., 1999;
Thimme et al., 2003; Wieland et al., 2004). In the current
study, we examined the impact of antigen recognition
on the adoptively transferred CTLs themselves, focus-
ing on their activation profile, effector functions, and
expansion and contraction kinetics in the liver and
spleen of HBV transgenic recipients, and we related
these changes to the dynamics of viral replication, viral
gene expression, and liver disease. The results demon-
strate that target cells, in this case hepatocytes, talk
back to the CTLs, resulting in a sequential and oscilla-
tory response pattern in the CTLs that could have a
significant impact on the outcome of the host-virus in-
teraction during HBV infection.
Results
Induction and Characterization of HBsAg-Specific
CD8+ T Cell Response in Donor Spleen Cells
A group of 50 B6D2 mice were injected intramuscularly
with 100 g of plasmid encoding the HBV middle enve-
lope protein (pCMVS2.S) in order to prime a CD8+ T cell
response to HBsAg. 3–4 weeks later, they were intrave-
nously infected with 1 × 107 pfu of recombinant vac-
cinia virus that expresses the HBV major envelope pro-
tein (vHBs4). 14 days after the booster immunization,
the hierarchy of HBsAg-specific CD8+ T cells in the
spleen was analyzed by intracellular cytokine staining
(ICS) for IFNγ after 5 hr of in vitro stimulation with the
known HBsAg-derived, H-2d-, and H-2b-restricted CTL
epitopes ENV28, ENV190, ENV208, ENV362, and ENV364.
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dFigure 1. Characterization of HBsAg-Specific CD8+ T Cell Re-
psponse Induced by Intramuscular DNA Prime-Vaccinia Boost Im-
wmunization
EMice were first primed by intramuscular injection of 100 g of
pCMV-S2.S DNA that expressed HBV middle envelope protein. 2–3 c
weeks later, they were infected with 1 × 107 pfu of HBs4 that ex- s
presses HBV major envelope protein. 2 weeks later, mice were sac- d
rificed to obtain spleen cells. The hierarchy of CD8+ T cells to
tknown H-2b- and H-2d-restricted CTL epitopes was examined by
rusing ICS for IFNγ (A). The frequency of ENV28-CD8+ T cells was
wcompared by using dimer staining and ICS (B).
o
C
uAs shown in Figure 1A, the ENV28-specific CD8+ T cell
response was strongly immunodominant, representing
Cmore than 95% of the response to the tested peptides.
Therefore, the ENV28-specific CD8+ T cell response i
iwas monitored in the following experiments.
We then compared the number of ENV28-specific i
aCD8+ T cells that produced IFNγ in response to the
ENV28 peptide with the number of CD8+ T cells that w
ccould be detected with the corresponding ENV28-
dimer. As shown in Figure 1B, 5.2% ± 0.9% of total m
spleen cells (41% ± 7.0% of CD8+ T cells) express spe-ific TCRs that recognize ENV28-Ld complex detected
y ENV28-dimer, whereas 4.4% ± 0.5% of total spleen
ells (38% ± 4.31% of CD8+ T cells) produce IFNγ upon
he ENV28 peptide stimulation. Thus, at least 85% of
he ENV28-specific CD8+ T cells in donor spleen cells
ere able to produce IFNγ.
ynamics of Antiviral Effector Functions
n the Liver
n this study, we adoptively transferred 2 × 108 immu-
ized spleen cells containing w10.4 × 106 ENV28-spe-
ific CD8+ T cells into 24 age-, sex-, and serum HBeAg-
atched lineage 1.3.32 transgenic mice and into 24
HC-matched nontransgenic littermates. Lineage
.3.32 transgenic mice express all of the HBV antigens
nd replicate HBV in the liver and kidney (Guidotti et
l., 1995). Groups of three mice were sacrificed at the
ndicated time points after adoptive transfer, and their
ntrahepatic, splenic, and peripheral blood lympho-
ytes were harvested for analysis of the total number
f ENV28-specific CD8+ T cells present. In order to cor-
elate the intrahepatic ENV28-specific CD8+ T cell re-
ponse with downstream antiviral and immunopatho-
ogical events, total liver DNA and RNA were isolated
nd analyzed for IFNγ and T cell messenger RNA
mRNA) expression by RNA protection assay (RPA),
BV replicative DNA content by Southern blot, HBV
RNA content by Northern blot, and evidence of liver
isease by quantitating serum alanine aminotransfer-
se (sALT) activity, as previously described (Guidotti et
l., 1996).
As shown in Figure 2A, within 4 hr after transfer,
NV28-specific CD8+ T cells were already detectable
n the liver (white bars) and spleen (black bars) of the
ransgenic recipients, and equivalent numbers of
NV28-specific CD8+ T cells were detected in the non-
ransgenic recipient controls (Figure S1 available in the
upplemental Data with this article online). The number
f ENV28-specific CD8+ T cells in the liver of the trans-
enic recipients remained constant for the next 2 days,
fter which they expanded rapidly, reaching levels on
ay 7 more than 25 times higher than the 4 hr time
oint, after which they gradually declined (Figure 2A,
hite bars). Interestingly, the intrahepatic expansion of
NV28-specific CD8+ T cells appeared to have oc-
urred at the expense of their counterparts in the
pleen (Figure 2A, black bars), which were no longer
etectable between days 1–5 at the same time that
hey were expanding in the transgenic liver and which
eturned to the spleen as their counterparts in the liver
ere contracting. These changes reflected antigen rec-
gnition, because the number of HBV ENV28-specific
D8+ T cells in the nontransgenic livers and spleens were
nchanged throughout the experiment (Figure S1).
As shown in Figure 2B, the number of ENV28-specific
D8+ T cells in the liver correlated very well with the
ntrahepatic CD8 and CD3 mRNA content, gradually
ncreasing by 10- to 20-fold by day 7 and then declin-
ng. In contrast, the IFNγ mRNA content rapidly peaked
t 4 hr, at which time the CD3 and CD8 mRNA signals
ere barely detectable. Subsequently, the IFNγ mRNA
ontent declined as the strength of the CD3 and CD8
RNA signals increased, suggesting that the ability ofENV28-specific CD8+ T cells to produce IFNγ de-
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55Figure 2. Kinetics of ENV28-Specific CD8+ T Cells and Their Antivi-
ral Effector Functions in the Liver
(A) Kinetics of ENV28-specific in the liver (white) and spleen (black)
of HBV transgenic mice. The data represent mean ± SD of three
mice.
(B) Kinetics of T cells markers and cytokine mRNA expression in
the liver. Total RNA (10 g) isolated from liver samples was ana-
lyzed for the expression of IFNγ, CD8, CD3, and L32 by an RNase
protection assay (RPA). The L32 was used to normalize the amount
of RNA loaded in each lane.
(C) Effect of ENV28-specific CD8+ T cells on HBV replication in the
liver. Southern blot analysis (S.B.) of 30 g of total liver DNA iso-
lated from the same mice. Bands corresponding to the expected
size of the integrated transgene (Tg), relaxed circular (RC), and sin-
gle-stranded (SS) HBV DNA were indicated. Bands corresponding
to the integrated transgenes can be used to normalize the amount
of DNA bound to the membrane.
(D) Effect of ENV28-specific CD8+ T cells on HBV gene expression
in the liver. Northern blot analysis (N.B.) of 20 g of total liver RNA
isolated from the same mice. GAPDH was used to normalize the
amount of RNA bound to the membrane.
(E) Serum alanine aminotransferase (sALT) activity in the same mice
is expressed as units/liter. The data represent mean ± SD of three
mice.creased as the T cells expanded. As expected, HBV
replicative intermediates almost completely disap-
peared from the liver as early as day 1 (Figure 2C) with-out a decrease in viral gene expression (Figure 2D) or
a proportional increase in sALT activity (Figure 2E), sug-
gesting that the rapid burst of IFNγ production inhibited
viral replication noncytolytically and posttranscription-
ally, as previously described (Guidotti et al., 1996). Note
that sALT activity increased in concert with the increase
in CD3 and CD8 mRNA content in the liver, suggesting
that they were related events. Note also that the sALT
activity peaked (Figure 2E) and viral RNA began to de-
cline (Figure 2D) on day 5, after which the viral RNA
virtually disappeared and the sALT activity declined,
suggesting a relationship between these events as well.
These findings were reinforced by the observations that
the number of ENV28-specific CD8+ T cells (Figure 2A),
the intrahepatic IFNγ, CD3, and CD8 mRNA levels (Fig-
ure 2B), and the sALT activity (Figure 2E) returned to or
toward baseline once the viral RNA was undetectable,
suggesting that antigen recognition was decreasing as
a result of the suppression of viral gene expression
(Figure 2D). The inhibition of viral RNA expression also
coincided with the reappearance of ENV28-specific
CD8+ T cells in the spleen (Figure 2A), suggesting that
the tissue tropism or compartmentalization of the
ENV28-specific CD8+ T cells is tightly regulated by the
level of viral antigen synthesis in the liver.
The expansion in the number of intrahepatic ENV28-
specific CD8+ T cells could be due to their proliferation
in situ or their recruitment from the spleen. To distin-
guish between these alternatives, we labeled the
primed spleen cells with 5,6-carboxyfluorescein diacet-
ate succinimidyl estater (CFSE) before transferring
them into transgenic and nontransgenic mice. Groups
of three transgenic and nontransgenic mice were sacri-
ficed 2.5 days and 5 days later, and the cell divisions
of the ENV28-specific CD8+ T cells in the liver were
monitored. As shown in Figure 3, a fraction of ENV28
specific had already divided up to five times by day 2.5
after the transfer, and they continued to divide until the
majority of ENV28-specific CD8+ T cells had dividedFigure 3. Rapid Cell Division of ENV28-Specific CD8+ T Cells in
the Liver
2 × 108 of HBsAg-immunized spleen cells were labeled with 10 M
CFSE and transferred to either HBV transgenic or nontransgenic
mice. The cell divisions of ENV28-specific CD8+ T cells in the liver
were monitored on days 2.5 and 5 after the transfer. Histograms
represent the ENV28-dimer+/CD8+ cells in HBV transgenic (white)
and nontransgenic liver (gray).more than six times 5 days later, suggesting that the
Immunity
56massive expansion of intrahepatic ENV28-specific
CD8+ T cells shown in Figure 2A reflects their prolifera-
tion in situ. In contrast, CFSE-labeled spleen cells did
not divide when they were transferred into nontrans-
genic littermates (Figure 3, shaded peaks), suggesting
that cell division in the transgenic recipients was trig-
gered by antigen recognition.
Intrahepatic Antigen Recognition Triggers
Phenotypic and Functional Changes in the ENV28-
Specific CD8+ T Cell Populations in the Liver
The results described above suggest that the effector
function of ENV28-specific CD8+ T cells rapidly evolved
as they proliferated in the liver of HBV transgenic mice.
To characterize that specific response, in the same ani-
mals displayed in Figure 2, we used multicolor FACS
analysis to determine the extent to which the ENV28-
specific CD8+ T cells in their livers and spleens coex-
pressed CD25, CD69, and IFNγ at various time points
after adoptive transfer, with IFNγ production being ex-
amined both directly ex vivo and after in vitro stimula-
tion by the ENV28 peptide. The results were compared
with the donor spleen cells in Figure 4. To examine the
impact of antigen recognition on the expression of
these markers, we compared them with the steady-
state content of hepatic HBV RNA, which is displayed
in Figure 4A as the ratio of HBV RNA:GAPDH mRNA
calculated from the Northern blot results shown in Fig-
ure 2D.
As shown in Figures 4B and 4C (white bars), the
ENV28-specific CD8+ T cells in the liver of the trans-
genic recipients were very rapidly activated, because
most of them expressed CD25+ (52%) and CD69+ (74%)
at the 4 hr time point (Figure 4B and 4C). This presuma-
bly reflects antigen recognition, because neither marker
was induced in the spleen of the same transgenic re-
cipients (Figures 4B and 4C, black bars) or in the liver
or the spleen of nontransgenic recipient controls (data
not shown). By day 1, the fraction of ENV28-specific
CD8+ T cells that expressed CD25 and CD69 cells in-
creased further, reaching a peak of 76.9% and 88.4%,
respectively, suggesting that nearly all the ENV28-spe-
cific CD8+ T cells that entered the liver had recognized
antigen and were activated during the first 24 hr after
adoptive transfer. Interestingly, the fraction of intrahep-
atic ENV28-specific CD8+ T cells that expressed CD25
started to decrease on day 2, and CD25 was no longer F
Sdetectable by day 7, even though the total number of
ENV28-specific T cells had expanded at least 20-fold T
sby that time (Figure 2A). Importantly, the decline in
eCD25 expression mirrored the decline in HBV gene ex-
Hpression in the liver, strongly suggesting that CD25 ex-
T
pression was antigen driven. Surprisingly, the number e
of CD69+ T cells remained high and virtually unchanged o
in the liver of these mice for at least 28 days after the r
ptransfer, despite the disappearance of HBV RNA. These
tunexpected results suggest that, despite the cessation
rof antigen synthesis, the ENV28-specific CD8+ T cells
were exposed to antigen throughout the experiment,
implying that less antigen is required to induce CD69 c
hthan CD25.
Antigen recognition also triggered interesting changes E
rin the effector function of the ENV28-specific CD8+ Tigure 4. Phenotypical and Functional Characterization of ENV28-
pecific CD8+ T Cells
he kinetics of activation marker and IFNγ expression by ENV28-
pecific CD8+ T cells in the liver (white) and spleen (black) were
xamined at indicated time points after the adoptive transfer to
BV transgenic mice.
he ratio of HBV RNA and GAPDH was calculated from the North-
rn blot results shown in Figure 2D (A). (B) and (C) show the kinetics
f CD25 and CD69 expression on the ENV28-dimer-positive cells,
espectively. (D) and (E) show the fraction of ex vivo (i.e., without
eptide stimulation) and in vitro (i.e., with ENV28 peptide stimula-
ion) IFNγ-producing CD8+ T cells in the liver, respectively. The data
epresent mean ± SD of three mice.ells in the liver of the transgenic recipients. Within 4
r after adoptive transfer, virtually all of the intrahepatic
NV28-specific CD8+ T cells produced IFNγ both di-
ectly ex vivo (Figure 4D) and after in vitro peptide stim-
Oscillating CD8+ T Cell Effector Functions In Vivo
57ulation (Figure 4E), similar to the induction of CD25 (Fig-
ure 4B) and CD69 (Figure 4C). Surprisingly, however, the
ability of these cells to produce IFNγ decreased rapidly
thereafter, becoming almost undetectable ex vivo on
day 7 (Figure 4D). Importantly, the frequency of IFNγ-
producing ENV28-specific CD8+ T cells returned to
baseline (Figure 4E) by day 28, mirroring the cessation
of HBV gene expression (Figure 4A) and contraction of
the intrahepatic ENV28-specific CD8+ T cell infiltrate
(Figure 2A). None of these changes occurred in the non-
transgenic livers and spleens (data not shown), indicat-
ing that they reflected antigen recognition. We also
monitored TNFα, IL-2, and IL-4 expression in the
ENV28-specific CD8+ T cells after ENV28 peptide stim-
ulation in vitro. w50% of the IFNγ-producing CD8+ T
cells in the donor spleen cell population expressed
TNFα, but not IL-2 or IL-4, prior to transfer. After
transfer, however, none of these cytokines was ex-
pressed by the intrahepatic ENV28-specific CD8+ T
cells either directly ex vivo or after in vitro peptide stim-
ulation (data not shown).
HBcAg-Specific CD8+ T Cells Are Also
Compartmentalized and Impaired in Their Ability to
Produce IFN after Antigen Recognition in the Liver
To determine whether the rapid sequestration and
downregulation of IFNγ production by HBV-specific
CD8+ T cells are ENV28-specific events, we transferred
HBcAg-primed spleen cells containing CD8+ T cells
specific for an immunodominant Kb-restricted CTL epi-
tope located between residues 93 and 100 in the core
protein (Kuhrober et al., 1997). As shown in Figure S2A,
spleen cells containing w0.25% COR93-specific, IFNγ-
positive CD8+ T cells (Figure S2A) were adoptively
transferred into HBV transgenic mice. As shown in Fig-
ure S2B, 5 days after transfer,w6.7% of the total intra-
hepatic CD8+ T cell population was COR93 specific,
whereas no COR93-specific CD8+ T cells were de-
tected in the spleen. Importantly, like the ENV28-spe-
cific CD8+ T cell population, only 0.55% of the day 5
intrahepatic CD8+ T cells were able to produce IFNγ
after peptide stimulation in vitro. These results suggest
that intrahepatic sequestration and functional impair-
ment occur after CD8+ T cells recognize antigen in the
liver irrespective of the antigen specificity of the T cells.
Delayed Induction of ENV28-Specific CD8+ T Cell
GrB Expression, In Vitro Cytolytic Activity,
and In Vivo Pathogenic Potential
To determine whether intrahepatic antigen recognition
also modulates the cytolytic activity and pathogenic
potential of ENV28-specific CD8+ T cells, we monitored
the intracellular content of grB and the cytolytic activity
of primed donor spleen cells and intrahepatic lympho-
cytes before and after adoptive transfer, respectively.
As shown in Figure 5A, grB expression was very low or
undetectable in the donor spleen cells and in the 4 hr
intrahepatic lymphocytes (IHL) population, but it in-
creased on days 3 and 5 as the T cells expanded (Fig-
ure 2A) and as sALT activity increased in vivo (Figure
2E). This contrasted strikingly with the decrease in IFNγ
production that was observed in the same time period
(Figures 4D and 4E).Figure 5. Delayed but Sustained Kinetics of Granzyme B Expres-
sion and In Vitro Cytolytic Activity of ENV28-Specific CD8+ T Cells
(A) Intracellular granzyme B (grB) expression of ENV28-specific
CD8+ T cells in donor spleen cells and IHLs from HBV transgenic
(white histograms) and nontransgenic (gray histograms) at 4 hr, day
3, and day 5 after adoptive transfer.
(B) Donor spleen cells and IHLs from HBV transgenic mice were
tested for cytotoxicity in a 5 hr 51Cr release assay ex vivo. To com-
pare cytotoxicity on a per cell basis, the effector:target (E:T) ratios
were adjusted based on the frequency of ENV28-dimer-positive
cells.To determine whether the grB content in ENV28-spe-
cific CD8+ T cells reflected their cytolytic activity, vary-
ing numbers of donor spleen cells and day 3 and day 5
IHLs were incubated with P815preS1 target cells that
express HBsAg or with parental P815 cells as a nega-
tive control. The effector:target (E:T) ratio was normal-
ized based upon the frequency of ENV28-dimer-posi-
tive cells in the populations in order to compare the
cytolytic activity on a per cell basis. As shown in Figure
5B, ENV28-specific CD8+ T cells in the donor spleens
exhibited relatively weak cytolytic activity. In contrast,
the intrahepatic ENV28-specific CD8+ T cells were
highly cytolytic on day 3, and they remained so on day
5, showing good correlation between grB content and
cytolytic activity. Collectively, these results demon-
strate that the induction of cytolytic activity of ENV28-
specific CD8+ T cells was relatively delayed but sus-
tained in the transgenic recipients, in contrast to their
ability to produce IFNγ, which was rapidly induced and
then declined. The results also illustrate the existence
of a close temporal relationship between these in vitro
parameters (Figures 5A and 5B) and the pathogenic po-
Immunity
58dtential of the ENV28-specific CD8+ T cells in vivo (Fig-
sure 2E).
c
w
dAnalysis of TCR Usage
cThe inverse relationship of the proliferative/cytolytic
Pand the IFNγ-producing capacities of the intrahepatic
uENV28-specific CD8+ T cells after antigen recognition
acould reflect either the preferential clonal expansion of
ea highly cytopathic-IFNγ-nonproducing CD8+ T cell
subpopulation or the global expansion of the original
cpopulation coupled with the downregulation of their
mIFNγ-producing capacity. To distinguish between these
nalternatives, we compared the TCR usage of the
CENV28-specific CD8+ T cells in donor spleen cells and
bIHLs isolated on day 5 after transfer by using a panel
fof murine Vβ chain-specific monoclonal antibodies cov-
tering 15 Vβ chain subfamilies. As shown in Figure 6,
t
w74% of the ENV28-specific CD8+ T cells in the donor
v
spleen cells were detected by the panel of antibodies,
t
reflecting the existence of polyclonal TCR repertoire. 5 a
days later, 85% of the ENV28-specific CD8+ T cells in (
the liver were detected by the antibodies, and their TCR t
usage was not significantly different from the donor u
spleen cell population. The potential expansion of a p
TCR subset that isn’t represented in the TCR-specific e
monoclonal antibody panel cannot explain the increase t
of IFNγ-nonproducing CD8+ T cells, because the frac- d
tion of ENV28-specific CD8+ T cells detected by the C
antibody panel increased after expansion in the liver. c
Collectively, these results strongly suggest that the in- c
crease in grB production and cytolytic activity and the t
decrease in IFNγ production observed during the ex- t
pansion phase were due to functional modulation of a c
globally expanding CD8+ T cell population in response N
to antigen recognition in the liver rather than the clonal g
expansion of a cytolytic but IFNγ-nonproducing subset.E
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Figure 6. Analysis of TCR Vβ Usage within ENV28-Specific CD8+
rT Cells
oENV28-specific CD8+ T cells in donor spleen cells (black) and day
t5 IHLs from HBV transgenic mice (white) were analyzed for their
cTCR Vβ usage. The percentages of ENV28-specific CD8+ T cells
that are recognized by each of the anti-Vβ Abs are shown. The data c
represent mean ± SD of three mice. s
f
aNV28-Specific Memory CD8+ T Cells Undergo
unctional Oscillation Irrespective of Their
aturation Stage
o determine if the potential for functional oscillation in
D8+ T cells persisted more than 2 weeks after immuni-
ation, we adoptively transferred DNA-primed, vac-
inia-boosted spleen cells harvested 4 weeks after im-
unization into HBV transgenic mice. The degree of
oexpression of IFNγ and TNFα in the ENV28-specific
D8+ T cells was used as an index of maturation. As
hown in Figure S3, the percentage of IFNγ-producing
NV28-specific CD8+ T cells that also produce TNFα
n the donor peripheral blood lymphocyte population
ncreased as a function of time after immunization from
5% at week 2 to 75.9% at week 4, indicating that mat-
ration had occurred. In addition, these cells were
D62L low, indicating that they were effector memory
ather than central memory CD8+ T cells. Spleen cells
btained from these mice on week 4 were adoptively
ransferred into HBV transgenic and nontransgenic re-
ipients, and we monitored the number of ENV28-spe-
ific CD8+ T cells in the recipient livers exactly as de-
cribed in Figure 2A. In addition, we examined the
requency of ENV28-specific CD8+ T cells in the hepatic
nd superficial (axillary and inguinal) lymph nodes to
etermine whether any changes that might be ob-
erved in the liver could reflect events that actually oc-
urred in lymphocytes in the draining lymph nodes,
hich subsequently migrated into the liver. Finally, we
etermined the frequency of ENV28-specific CD8+ T
ells that coexpress CD25, CD122, CD69, CD62L, IFNγ,
D-1, CTLA-4, and grB, as well as the frequency of reg-
latory (CD4+CD25+) T cells, at various time points after
doptive transfer to determine if functional oscillation
xtended to these markers as well.
The adoptively transferred ENV28-specific CD8+ T
ells became activated in the liver of HBV transgenic
ice (Figure 7), but not nontransgenic littermates (data
ot shown), similar to the results shown in Figure 4.
D69 expression (Figure 7B) was markedly increased
y 4 hr after adoptive transfer and remained elevated
or the duration of the experiment, suggesting persis-
ent antigen recognition by the T cells. Antigen recogni-
ion triggered rapid induction of IFNγ in the T cells ex
ivo (Figure 7C) at 4 hr after adoptive transfer. However,
heir ability to produce IFNγ decreased rapidly there-
fter, becoming almost undetectable ex vivo on day 3
Figure 7C), despite continued HBV gene expression at
hat time (Figure 7A), similar to the results shown in Fig-
re 4D. Furthermore, the ability to produce IFNγ upon
eptide stimulation followed the same kinetics. Inter-
stingly, the rapid suppression of IFNγ production by
he ENV28-specific CD8+ T cells correlated with in-
uction of PD-1 on the T cells (Figure 7E), whereas
TLA-4 expression was never detectable on these
ells, and the frequency of regulatory T cells did not
hange (data not shown). These results suggest that
he downregulation of IFNγ production may be due to
he suppressive influence of signaling via the PD-1 re-
eptor (Freeman et al., 2000; Latchman et al., 2001).
one of these changes was observed in the nontrans-
enic littermates (data not shown).
After these events, the intrahepatic ENV28-specific
Oscillating CD8+ T Cell Effector Functions In Vivo
59Figure 7. ENV28-Specific Memory CD8+ T
Cells Also Undergo Functional Oscillation
upon the Antigen Recognition in the Liver Ir-
respective of Their Maturation Stage
Mice were immunized by DNA-prime, vac-
cinia boost immunization exactly as de-
scribed in Figure 1. 4 weeks later, mice were
sacrificed to obtain spleen cells, and 1 × 108
of spleen cells were transferred to HBV
transgenic mice or nontransgenic litter-
mates. (A) HBV gene expression. Northern
blot analysis was performed exactly as de-
scribed in Figure 2, and the ratio of HBV RNA
and GAPDH was shown. The fraction of
ENV28-dimer-positive CD8+ T cells that
coexpressed a wide variety of phenotypic
and functional markers as a function of time
after adoptive transfer were determined as
described in the experimental procedures.
These markers included CD69 (B), IFNγ
either ex vivo (C) or after in vitro peptide
stimulation (D), PD-1 (E), CD25 (G), CD122
(H), and grB (I). The number of intrahepatic
ENV28-specific CD8+ T cells is displayed in
(F), and the sALT activity in the same mice
(expressed as units/liter) is shown in (J). The
data represent mean ± SD of three mice.CD8+ T cells greatly expanded by more than 20-fold on
day 7, after which they declined. In contrast, the num-
ber of intrahepatic ENV28-specific CD8+ T cells was
stable in the nontransgenic recipients during the entire
observation period (see Figure S1B). Importantly,
ENV28-specific CD8+ T cells were not detectable in the
hepatic lymph nodes until day 5 (Figure S4), whereas
they were detectable as early as 4 hr in the liver (Figures
2A and 7F), supporting the notion that expansion of in-
trahepatic ENV28-specific CD8+ T cells shown in Figure
3 reflects their proliferation in situ rather than recruit-
ment of actively proliferating cells from the lymph
nodes. As shown in Figure 7G, CD25 expression began
to increase as early as 4 hr after adoptive transfer,
reached a peak on day 3, and rapidly decreased to
baseline level by day 7. Similar to the kinetics of T cell
expansion shown in Figure 7F, CD122 (IL-2β receptor)
expression (Figure 7H) was induced more slowly than
CD25, reaching peak levels on days 3–5 and decreasingtoward baseline thereafter. Interestingly, as IFNγ ex-
pression declined (Figures 7C and 7D), the ability of the
ENV28-specific CD8+ T cells to express grB increased
progressively until day 7, at which point virtually all of
them were grB positive and they remained so until at
least day 21. Importantly, sALT activity increased (Fig-
ure 7J) as the number of ENV28-specific CD8+ T cells
(Figure 7F) that expressed grB (Figure 7I) increased in
the liver, and it decreased on day 21, reflecting a 10-
fold drop in the number of intrahepatic ENV28-specific
CD8+ T cells (Figure 7F). Finally, the intrahepatic
ENV28-specific CD8+ T cells did not express CD62L at
any time after adoptive transfer (data not shown), indi-
cating that they were not central memory T cells (Maso-
pust et al., 2001; Sallusto et al., 1999). These results
are similar to those observed after adoptive transfer of
spleen cells 2 weeks after immunization, as described
in Figures 2A and 4. Taken together, the data suggest
that intrahepatic antigen recognition triggers functional
Immunity
60oscillation in the ENV28-specific CD8+ T cells irrespec- m
ative of their maturation stage at the time of adoptive
Ttransfer.
s
wDiscussion
C
pThe current study was designed to address the impact
gof intrahepatic antigen recognition on the dynamics of
ea virus-specific memory CD8+ T cell response. The re-
tsults revealed previously unappreciated crosstalk be-
Ttween the antigen-positive liver cells and the virus-spe-
cific CD8+ T cell population.
vAfter adoptive transfer, HBV-specific CD8+ T cells be-
Hhaved entirely differently in the liver and spleen of HBV
ntransgenic mice. The intrahepatic ENV28-specific CD8+
aT cells became rapidly activated to express CD25 and
lCD69, and they rapidly produced IFNγ (directly ex vivo),
Kwhich was followed by the disappearance of HBV DNA
preplicative intermediates from the liver, in keeping with
ethe known inhibitory effect of IFNγ on HBV replication
r(Guidotti et al., 1996; Kakimi et al., 2000). The intrahe-
Tpatic ENV28-specific CD8+ T cells subsequently un-
dderwent rapid cell division and massive expansion, dur-
fing which most of them converted to a CD25−/CD69+
dphenotype. The rapid cell division presumably occurred
rin the liver, because ENV28-specific CD8+ T cells were
anot detectable in the hepatic lymph nodes until day 5
I(Figure S4), whereas they were easily detectable in the
dliver as early as 4 hr after transfer (Figures 2A and 7F
eand Figure S4), and they were actively dividing in the
aliver by day 2.5 after transfer (Figure 3). As the CTLs
wwere expanding and acquiring grB expression, serum
tALT activity increased and HBV gene expression was
oextinguished, at which point the number of ENV28-spe-
2cific CD8+ T cells began to decline. Unexpectedly, even
s
before ENV28-specific CD8+ T cells began to expand,
s
they lost the ability to produce IFNγ (both ex vivo and
N
after peptide stimulation), demonstrating the rapid but
p
transient nature of cytokine production by the ENV28- s
specific CD8+ T cells. In contrast, the cytolytic activity l
of ENV28-specific CD8+ T cells increased as they were t
expanding and losing the ability to produce IFNγ. Fur- a
thermore, the behavior of HBV-specific CD8+ T cells in d
the liver was very different from their counterparts in m
the spleen, because the virus is only produced in the t
liver and kidney of these animals, not in the spleen or I
other lymphoid organs. Indeed, the ENV28-specific c
CD8+ T cells completely disappeared from the spleen T
within 24 hr, and they did not reappear until day 7, at C
which point viral RNA was no longer detectable in the e
liver. We believe that the disappearance of these cells s
from the spleen presumably reflects their rapid seque- c
stration in the liver rather than massive cell death in
situ, because they did not show evidence of antigen e
recognition in the spleen (Figures 4B–4D, black bar). e
Interestingly, a small fraction of splenic CD8+ T cells o
produced IFNγ ex vivo when the ENV28-specific CD8+ (
T cells reappeared in the spleen, perhaps reflecting an- s
tigen presentation by dendritic cells that have pro- s
cessed antigen from apoptotic hepatocytes, because m
this occurred during and after the peak of sALT activity. T
Importantly, the sequestration and functional impair- m
ament was independent of the antigen specificity oraturation stage of the T cells because it was observed
fter transfer of both ENV28- and COR93-specific CD8+
cells into these animals and after transfer of ENV28-
pecific CD8+ T cells obtained from donor mice 4
eeks after DNA-prime, vaccinia boost immunization.
ollectively, these results demonstrate that antigen
resentation by hepatocytes (i.e., nonprofessional anti-
en-presenting epithelial cells in the liver) has a profound
ffect on the activation state, dynamics, compartmen-
alization, and effector function of virus-specific CD8+
cells in vivo.
It is noteworthy that the expression of two major acti-
ation markers, CD25 and CD69, by the intrahepatic
BV-specific CD8+ T cells displayed very different ki-
etics in these experiments. CD25 is required for high-
ffinity binding of IL-2, and its expression level is regu-
ated by TCR signaling and IL-2 (Depper et al., 1985;
im and Leonard, 2002; Leonard et al., 1982). CD69 ex-
ression is also regulated by TCR signaling and is gen-
rally regarded as the most sensitive marker for antigen
ecognition by CD8+ T cells (Castellanos et al., 1997;
esti et al., 1989). We do not understand why CD25 was
ownregulated in this study. Further, in view of those
indings, we don’t understand why CD69 was not
ownregulated, because both were induced by antigen
ecognition. It is possible that stronger antigenic stimuli
re necessary to sustain CD25 expression than CD69.
t is also possible that autocrine or paracrine IFNγ pro-
uced by ENV28-specific CD8+ T cells regulates CD25
xpression by previously unrecognized mechanisms,
s its kinetics followed the kinetics of IFNγ production
ith a slight delay. Because IL-2 is required for the sus-
ained expansion of CD8+ T cells within nonlymphoid
rgans (D’Souza and Lefrancois, 2003; D’Souza et al.,
002), it is not surprising that the intrahepatic ENV28-
pecific CD8+ T cell population began to contract
hortly after CD25 expression became undetectable.
onetheless, the sustained upregulation of CD69 ex-
ression by the HBV-specific intrahepatic CD8+ T cells
trongly suggests that antigen was still present at some
evel in the liver and that CD69 induction is more sensi-
ive than CD25 as an indicator that low levels of antigen
re present. Interestingly, expression of CD122 was in-
uced more slowly than CD25 and appeared to be
ore closely associated with T cell expansion and con-
raction. CD122 is the β subunit shared by the IL-2 and
L-15 receptors and responsible for IL-15-dependent T
ell proliferation (Judge et al., 2002; Zhang et al., 1998).
he delayed kinetics of CD122 expression relative to
D25 may suggest that the signaling via CD25 is nec-
ssary for the upregulation of CD122 and that the
witch from IL-2 to IL-15 responsiveness may have oc-
urred in the expanding T cells.
The differential kinetics of noncytolytic and cytolytic
ffector functions of CD8+ T cells was particularly inter-
sting. Rapid IFNγ expression and delayed emergence
f cytotoxicity are characteristics of memory T cells
Slifka et al., 1999; Wolint et al., 2004). However, these
tudies were performed in vitro and reflected the re-
ponse to peptide stimulation. The current results de-
onstrate that IFNγ is rapidly induced in memory CD8+
cells in vivo, as shown by the rapid induction of IFNγ
RNA in the liver after adoptive transfer and by the
bility of the corresponding intrahepatic lymphocytes
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61to produce IFNγ directly ex vivo, i.e., without peptide
stimulation, as early as 4 hr after they entered the liver.
Furthermore, we showed that the absolute number of
intrahepatic CD8+ T cells was relatively low at that early
time point but those cells displayed the highest level of
IFNγ production at any time point examined both by
intracellular cytokine staining and by RPA. Although it
is theoretically possible that inflammatory cells other
than ENV28-specific CD8+ T cells could have contrib-
uted to the rapid induction of IFNγ mRNA expression in
vivo, we consider this unlikely for the following reasons.
First, ex vivo IFNγ-producing CD8+ T cells were not ob-
served after adoptive transfer into nontransgenic litter-
mates, suggesting that IFNγ induction was antigen spe-
cific. Second, more than 95% of all the functional
HBsAg-specific CD8+ T cells were ENV28 specific (Fig-
ure 1), making it unlikely that subdominant CD8+ T cells
contributed to the IFNγ production. Third, the IFNγ-pro-
ducing CD8+ T cells did not express DX5 (data not
shown), ruling out the possibility that the IFNγ-produc-
ing cells were NK or NKT cells. In addition, we have
previously shown that the same amount of IFNγ is pro-
duced in the liver after the adoptive transfer of ENV28-
specific CD8+ T cell clones into IFNγ-deficient HBV
transgenic mice and wild-type HBV transgenic mice
(McClary et al., 2000), suggesting that the intrahepatic
IFNγ is being produced by the adoptively transferred
virus-specific CD8+ T cells and not host-derived anti-
gen-nonspecific inflammatory cells in the liver. Taken
together, the results suggest that maximum IFNγ ex-
pression in the liver is achieved very rapidly by small
numbers of antigen-specific CD8+ T cells and that this
inhibits viral replication very effectively even before the
massive expansion of the T cells in the liver.
Perhaps the most unexpected result in this study was
the early loss of the ability of the HBV-specific CD8+ T
cells to produce IFNγ in the liver. We suggest that this
reflects the functional impairment of ENV28-specific
CD8+ T cells by sustained antigen stimulation rather
than by the loss of antigenic stimulation, because the
intrahepatic HBV mRNA level did not decrease until 3
days or more after adoptive transfer, yet the IFNγ-pro-
ducing population had decreased byw90% during this
interval. In contrast, the in vitro cytolytic activity and
the cytopathic effect of the ENV28-specific CD8+ T cells
emerged much later than their IFNγ-producing capac-
ity; indeed, they appeared as IFNγ levels were waning.
Importantly, the rapid loss of IFNγ-producing capacity
of the ENV28-specific CD8+ T cells and the delayed in-
duction of their cytolytic activity were not due to the
preferential expansion of a highly cytolytic IFNγ nonpro-
ducing CD8+ T cell population, because the TCR usage
of the ENV28-specific CD8+ T cells was not significantly
different before and after transfer. This is consistent
with the results reported by Fuller et al., in which CD8+
T cell exhaustion occurred without changes in TCR us-
age during chronic LCMV infection (Fuller et al., 2004).
Furthermore, the rapid induction and decline in IFNγ
production and delayed emergence of cytolytic activity
were similarly observed when matured memory T cells
(i.e., 1 month after DNA-prime, vaccinia boost immuni-
zation) were adoptively transferred to HBV transgenic
mice (Figure 7), suggesting that the intrahepatic antigen
recognition triggers functional oscillation in T cells irre-spective of their maturation stage at the time of adop-
tive transfer. Collectively, we suggest that the rapid loss
of IFNγ-producing capacity of ENV28-specific CD8+ T
cells and the delayed induction of their cytolytic activity
reflect the functional modification of the entire ENV28-
specific T cell population.
Interestingly, the loss of IFNγ expression coincided
with the strong induction of PD-1 on ENV28-specific
CD8+ T cells (Figure 7E). In contrast, CTLA-4 expres-
sion was never detectable on the HBV-specific T cells,
and no changes were observed in the frequency of in-
trahepatic regulatory (CD4+CD25+) T cells at any time
point after adoptive transfer (data not shown). PD-1
plays an important role in maintaining tolerance to au-
toantigens and tumors (Dong et al., 2002; Iwai et al.,
2002; Okazaki et al., 2003). Engagement of TCR and
PD-1 modulates TCR signaling by activating the tyro-
sine phosphatase SHP-2 (Latchman et al., 2001). We
therefore suggest that the downregulation of IFNγ pro-
duction by CD8+ T cells after antigen recognition in the
liver may be due to suppressive signaling via the upreg-
ulated PD-1 receptor. Experiments are currently un-
derway to test this hypothesis.
The importance of these results would be heightened
if they also occur during natural infections. Analysis of
the relative kinetics of cytokine production and cyto-
lytic activity during infection is difficult because virus-
specific CD8+ T cells are relatively infrequent during a
primary CD8+ T cells response. It is worth mentioning,
however, that serum IFNγ levels are induced before the
expansion of virus-specific CD8+ T cells during primary
LCMV infection (Pien et al., 2002). Furthermore, func-
tional impairment of CD8+ T cells has been extensively
studied in chronic LCMV infection. In contrast to our
study, however, the cytolytic activity of LCMV-specific
CD8+ T cells was more easily impaired than their IFNγ-
producing ability (Wherry et al., 2003a; Zhou et al.,
2004). We do not understand the basis for the differ-
ence, but it may reflect the nature of the target organs.
In our system, antigen recognition by HBV-specific
CD8+ T cells occurs almost exclusively in the liver,
where the antigen-expressing cells are not professional
antigen-presenting cells (APCs) and they are tightly
packed, whereas antigen recognition by LCMV-specific
CD8+ T cells occurs systematically in many cell types,
including dendritic cells and other professional APCs.
Further studies are warranted to examine the basis for
these differences. Interestingly, IFNγ gene expression in
the liver correlates with viral clearance and precedes
the onset of liver disease in acutely HBV-infected chim-
panzees (Chisari, 2000; Guidotti et al., 1999; Wieland et
al., 2004), and none of these events occurred when
CD8+ T cells were depleted at the peak of HBV infection
(Thimme et al., 2003). Thus, it is possible that sequen-
tial activation of noncytolytic and cytolytic CD8 T cell
effector functions occurs during HBV infection, LCMV
infection, and other viral infections as well.
In summary, the results described herein illustrate the
power of the HBV-positive liver to activate and seques-
ter HBV-specific CD8+ T cells in the liver, the prodigious
proliferative capacity of HBV-specific CD8+ T cells
within the liver, and the sequential and reciprocal nature
of the relationship between the IFNγ-producing and cy-
tolytic potential of those T cells. The data suggest that
Immunity
62vsequential stimulatory and inhibitory effects of antigen
drecognition on IFNγ production and cytolytic activity
pcould easily produce an oscillating cycle on which anti-
s
viral effector functions are alternately triggered and
suppressed by a fluctuating antigen burden. We are B
attracted by the hypothesis that these events could T
slimit the amount of tissue injury in the context of a vig-
dorous T cell response, and they could explain why IFNγ-
nonproducing but cytolytic T cells are commonly pre-
Ssent during persistent viral infections of the liver
S
(Lechner et al., 2000; Thimme et al., 2001). c
a
Experimental Procedures c
Mice A
HBV transgenic mouse lineage 1.3.32 (inbred C57BL/6, H-2b) has
been previously described (Guidotti et al., 1995). These animals ex- W
press all of the HBV antigens and replicate HBV in the liver and L
kidney at high levels without any evidence of cytopathology. Lin- C
eage 1.3.32 and C57BL/6 mice (H-2b) were bred for one generation a
against B10.D2 mice (H-2d) to produce F1 hybrids (designated N
B6D2). In all experiments, the mice were matched for age (8 S
weeks), sex (male), and HBeAg levels in their serum before experi- t
mental manipulations.
RPeptide, Plasmid, and Recombinant Vaccinia Virus
RPeptide, plasmid, and recombinant vaccinia viruses used in this
Astudy have been previously described (Ando et al., 1993; Ishikawa
Pet al., 1998; Kuhrober et al., 1997; Schirmbeck et al., 2003; Sette et
al., 2001). Details are provided in the Supplemental Experimental
RProcedures.
AImmunization of Mice and Adoptive Transfer
SB6D2 mice were immunized by using a plasmid DNA prime-vac-
ccinia virus boost regimen exactly as described (Kakimi et al., 2002).
f14 or 28 days after the booster immunization, mice were sacrificed,
and spleen cells were injected intravenously into syngenic trans- B
genic and nontransgenic recipients. Groups of three mice were r
sacrificed at various time points after transfer and their livers, B
lymph nodes, peripheral blood, and spleen were harvested for fur-
C
ther analysis. Detailed procedures can be found in the Supplemen-
p
tal Experimental Procedures.
l
s
CFSE Labeling
CCells were labeled with CFSE (Molecular Probes) as previously de-
nscribed (Kakimi et al., 2002).
1
DImmunofluorescent Staining and FACS Analysis
iRecombinant soluble dimeric H-2Ld:Ig and H-2Kb:Ig Fusion Protein
1(BD/PharMingen) complexed with HBV ENV28 peptide (ENV28-di-
Dmer) and COR93 peptide (COR93-dimer) were prepared according
(to the manufacturer’s instructions. Anti-mouse CD4, -CD8, -CD3,
p-CD25, -CD69, -CD62L, -CD122, PD-1, -CTLA-4, -TCRs, IFNγ,
-TNFα, -IL-2, and IL-4 (all purchased from BD/Pharmingen) and D
anti-human granzyme B (Caltag) were used as described in the T
Supplemental Experimental Procedures. Cells were acquired by s
using either a FACSCalibur flow cytometer (BD Bioscience) or Digi- 4
tal LSRII flow cytometer (BD Bioscience), and data were analyzed
D
by using CELLQuest software (BD Bioscience) or FlowJo (Tree
D
Star Inc.).
a
n
Cytotoxicity Assays
F51Chromium (Cr) release assays were performed directly ex vivo by
ausing 5 × 103 51Cr-labeled P815preS1 target cells that express
sHBsAg and control parental P815 cells as described (Ando et al.,
F1993).
m
(Tissue DNA and RNA Analyses
nTotal liver DNA and RNA were analyzed for HBV replicative interme-
adiates by Southern blot, for HBV RNA by Northern blot, and for
cytokine transcripts by RNase protection assay exactly as pre- Fiously described (Guidotti et al., 1995, 1996). The relative abun-
ance of specific DNA and RNA molecules was determined by
hosphor imaging analysis, using the Optiquant image analysis
oftware (Packard).
iochemical Analyses
he extent of hepatocellular injury was monitored by measuring
ALT activity at multiple time points after treatment as previously
escribed (Guidotti et al., 1995; Moriyama et al., 1990).
upplemental Data
upplemental Data include Supplemental Experimental Pro-
edures, Supplemental References, and four figures and are avail-
ble with this article online at http://www.immunity.com/cgi/
ontent/full/23/1/53/DC1/.
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